All 1 tracked stories fall under one category: telehealth. Of the tracked stories, 1 of 1 also mention Citi, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 5.9 for that window. They are better corroborated than the beat average, carrying 3 original sources each against 2.3 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Needham
All 1 tracked stories fall under one category: telehealth. Of the tracked stories, 1 of 1 also mention Citi, the most common co-covered peer. Their average consequence score of 7 runs above the beat's 5.9 for that window. They are better corroborated than the beat average, carrying 3 original sources each against 2.3 for the same window. Needham appears in 1 tracked Healthcare story from March 10, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Needham. Shared-story counts are live from our verified record — not editorial picks.
Hims & Hers Health has secured a strategic partnership with Novo Nordisk to distribute branded GLP-1 medications, effectively ending a high-stakes patent dispute. The deal marks a pivotal shift for the telehealth provider from compounded alternatives to FDA-approved Ozempic, triggering a massive 41% rally in its share price.